

Evidence dossier - Sarasin & Partners

GetCoattail manager profile: <https://getcoattail.com/manager/sarasin-partners> | CIK 0001510481 | Rank #57 of 149 tracked managers by reported 13F value.

Background: Founded: 1983 | HQ: London, United Kingdom | Style: Long-term thematic global equity and multi-asset investing with responsible stewardship | Key person: Guy Matthews

Background source: <https://pitchbook.com/profiles/advisor/57955-33>

1. Latest filing snapshot (as reported)

Period end: 2026-09-30 Filed: 2026-10-13 Reported total value: \$8.9B Positions: 111 Top-10 concentration: 53.5% of reported value.

Ticker	Company	Weight	Reported value
NVDA	Nvidia Corporation	9.62%	\$858M
GOOGL	Alphabet Inc	8.00%	\$714M
MSFT	Microsoft Corp	7.74%	\$691M
AAPL	Apple Inc	6.43%	\$574M
AMZN	Amazon Com Inc	5.09%	\$454M
MA	Mastercard Incorporated	4.13%	\$369M
CME	Cme Group Inc	3.88%	\$346M
AVGO	Broadcom Inc	3.27%	\$292M
BLK	Blackrock Inc	2.76%	\$246M
C	Citigroup Inc	2.55%	\$228M

2. Hypothetical 13F-clone results

Window: 2016-10-14 to 2026-10-02 (40 filings). Cumulative: +296.4% CAGR: +14.82% SPY same window: cumulative +322.9%, CAGR +15.57%. Trailing CAGR - 10Y: n/a, 5Y: +11.11%, 3Y: +20.05%, 1Y: +9.57%. Max drawdown (month-end, approximate): -25.3%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001085146-16-004493	2016-10-14	130
2016Q4	0001085146-17-000407	2017-02-10	120
2017Q1	0001085146-17-001322	2017-05-15	111
2017Q2	0001085146-17-001628	2017-08-03	110
2017Q3	0001085146-17-002302	2017-11-13	107
2017Q4	0001085146-18-000354	2018-02-06	110
2018Q1	0001085146-18-001190	2018-05-01	96

2018Q2	0001085146-18-001869	2018-08-07	103
2018Q3	0001085146-18-002562	2018-11-09	119
2018Q4	0001085146-19-000521	2019-02-12	113
2019Q1	0001085146-19-001461	2019-05-13	113
2019Q2	0001085146-19-001923	2019-07-18	124
2019Q3	0001085146-19-002785	2019-11-08	123
2019Q4	0001085146-20-000600	2020-02-12	120
2020Q1	0001085146-20-001262	2020-04-30	109
2020Q2	0001085146-20-001815	2020-07-17	112
2020Q3	0001085146-20-002812	2020-11-09	112
2020Q4	0001085146-21-000151	2021-01-19	109
2021Q1	0001085146-21-001381	2021-04-29	103
2021Q2	0001085146-21-001934	2021-07-13	107
2021Q3	0001085146-21-002870	2021-10-22	109
2021Q4	0001085146-22-000183	2022-01-19	96
2022Q1	0001085146-22-001359	2022-04-11	88
2022Q2	0001085146-22-002388	2022-07-13	88
2022Q3	0001085146-22-003470	2022-10-18	89
2022Q4	0001085146-23-000455	2023-01-30	90
2023Q1	0001085146-23-002084	2023-05-08	84
2023Q2	0001085146-23-002616	2023-07-11	81
2023Q3	0001085146-23-003586	2023-10-05	79
2023Q4	0001085146-24-000106	2024-01-10	84
2024Q1	0001085146-24-001748	2024-04-12	80
2024Q2	0001085146-24-003096	2024-07-19	83
2024Q3	0001085146-24-004737	2024-10-09	80
2024Q4	0001085146-25-000270	2025-01-16	62
2025Q1	0001085146-25-002097	2025-04-15	81
2025Q2	0001085146-25-003615	2025-07-09	80
2025Q3	0001085146-25-005903	2025-10-10	74
2025Q4	0001510481-26-000001	2026-01-08	77
2026Q1	0001510481-26-000002	2026-04-13	88
2026Q2	0001510481-26-000003	2026-07-07	94

4. Coverage and adjustments

Price coverage at the latest filing: 97.0% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.